Integrative radiogenomic profiling of squamous cell lung Cancer

Cancer Research

Volumn 73, Issue 20, 2013, Pages 6289-6298

  Abazeed, Mohamed E ^a   Adams, Drew J ^f,h   Hurov, Kristen E ⁱ   Tamayo, Pablo ^h   Creighton, Chad J ^k   Sonkin, Dmitriy ⁱ   Giacomelli, Andrew O ^b   Du, Charles ^b   Fries, Daniel F ^d   Wong, Kwok Kin ^d   Mesirov, Jill P ^h   Loeffler, Jay S ^c   Schreiber, Stuart L ^b,f,g,h,j   Hammerman, Peter S ^d,h   Meyerson, Matthew ^d,e,h  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f BioTherapeutics Chemistry   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^h BROAD INSTITUTE OF MIT AND HARVARD   (United States)

ⁱ NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^j Harvard University ^*  (United States)

^k BAYLOR COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUPARLISIB; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MESSENGER RNA; TRANSCRIPTION FACTOR NRF2;

ADAPTIVE IMMUNITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; COMPUTER MODEL; CONTROLLED STUDY; DETOXIFICATION; DOWN REGULATION; GENE; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENOMICS; GENOTOXICITY; HETEROZYGOSITY LOSS; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; INNATE IMMUNITY; INTERMETHOD COMPARISON; KEAP1 GENE; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MEASUREMENT ACCURACY; NFE2L2 GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIATION DOSE; RADIATION EXPOSURE; RADIATION RESPONSE; RADIATION SURVIVAL; RADIOGENOMICS; RADIOLOGICAL PARAMETERS; RADIOSENSITIVITY; TUMOR SUPPRESSOR GENE; VALIDATION PROCESS;

CARCINOMA, SQUAMOUS CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LUNG NEOPLASMS; NF-E2-RELATED FACTOR 2; PHOSPHATIDYLINOSITOL 3-KINASES; RADIATION TOLERANCE;

EID: 84886022329     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1616     Document Type: Article

References (50)

1. Curran WJ. New chemotherapeutic agents: update of major chemoradiation trials in solid tumors. Oncology 2002; 63(SUPPL. 2): 29-38.
2. Hammerman PS, Janne PA, Johnson BE Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2009; 15:7502-9.
3. Paez JG, Janne PA, Lee J.C., Tracy S., Greulich H, Gabriel S, et al EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500.
4. Kwak EL, Bang YJ, Camidge D.R., Shaw AT, Solomon B, Maki RG, et al Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693-703.
5. Amundson SA, Do KT, Vinikoor L.C., Lee RA, Koch-Paiz CA, Ahn J, et al Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res 2008; 68:415-24.
6. Eschrich S, Zhang H, Zhao H., Boulware D, Lee JH, Bloom G, et al Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. Int J Radiat Oncol Biol Phys 2009; 75: 497-505.
7. Torres-Roca J.F., Eschrich S, Zhao H., Bloom G, Sung J, McCarthy S., et al Prediction of radiation sensitivity using a gene expression classifier. Cancer Res 2005; 65:7169-76.
8. Puck TT, Marcus PI Action of x-rays on mammalian cells. J Exp Med 1956; 103:653-66.
9. Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumour Biol 2010; 31:363-72.
10. Bardelle C, Boros J. Development of a high-content high-throughput screening assay for the discovery of ATM signaling inhibitors. J Biomol Screen 2012; 17:912-20.
11. Tseng HM, Shum D, Bhinder B., Escobar S, Veomett NJ, Tomkinson A.E., et al A high-throughput scintillation proximity-based assay for human DNA ligase IV. Assay Drug Dev Technol 2012; 10:235-49.
12. Katz D, Ito E, Liu FF On the path to seeking novel radiosensitizers. Int J Radiat Oncol Biol Phys 2009; 73:988-96.
13. Auperin A, Le Pechoux C, Rolland E, Curran W.J., Furuse K., Fournel P, et al Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:2181-90.
14. Barretina J, Caponigro G, Stransky N., Venkatesan K, Margolin AA, Kim S, et al The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483:603-7.
15. Franken NA, Rodermond HM, Stap J, Haveman J., van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006; 1:2315-9.
16. Cai Z, Chattopadhyay N, Liu W.J., Chan C., Pignol JP, Reilly RM Optimized digital counting colonies of clonogenic assays using Image J software and customized macros: comparison with manualcounting. Int J Radiat Biol 2011; 87:1135-46.
17. Pendyala S, Moitra J, Kalari S., Kleeberger SR, Zhao Y, Reddy SP, et al Nrf2 regulates hyperoxia-induced Nox4 expression in human lung endothelium: identification of functional antioxidant response elements on the Nox4 promoter. Free Radic Biol Med 2011; 50: 1749-59.
18. Narisawa-Saito M., Handa K, Yugawa T., Ohno S, Fujita M, Kiyono T. HPV16 E6-mediated stabilization of ErbB2 in neoplastic transformation of human cervical keratinocytes. Oncogene 2007; 26:2988-96.
19. Moehlenkamp JD, Johnson JA Activation of antioxidant/electrophile responsive elements in IMR-32 human neuroblastoma cells. Arch Biochem Biophys 1999; 363:98-106.
20. Hammerman PS, Lawrence MS, Voet D, Jing R., Cibulskis K, Sivachenko A, et al Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489:519-25.
21. Carmichael J, Degraff WG, Gamson J, Russo D., Gazdar AF, Levitt ML, et al Radiation sensitivity of human lung cancer cell lines. Eur J Cancer Clin Oncol 1989; 25:527-34.
22. Duchesne GM, Eady JJ, Peacock J.H., Pera MF A panel of human lung carcinoma lines: establishment, properties, and common characteristics. Br J Cancer 1987; 56:287-93.
23. Itoh K, Chiba T, Takahashi S., Ishii T, Igarashi K, Katoh Y., et al An Nrf2/ small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236:313-22.
24. Itoh K, Wakabayashi N, Katoh Y., Ishii T, Igarashi K, Engel J.D., et al Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999; 13:76-86.
25. Jeyapaul J, Jaiswal AK Nrf2 and c-Jun regulation of antioxidant response element (ARE)-mediated expression and induction of gamma-glutamylcysteine synthetase heavy subunit gene. Biochem Pharmacol 2000; 59:1433-9.
26. Sjoberg L, Eriksen TE, Revesz L. The reaction of the hydroxyl radical with glutathione in neutral and alkaline aqueous solution. Radiat Res 1982; 89:255-63.
27. Singh A, Bodas M, Wakabayashi N., Bunz F, Biswal S. Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid Redox Signal 2010; 13:1627-37.
28. McDonald JT, Kim K, Norris A.J., Vlashi E., Phillips TM, Lagadec C, et al Ionizing radiation activates the Nrf2 antioxidant response. Cancer Res 2010; 70:8886-95.
29. Shibata T, Ohta T, Tong K.I., Kokubu A., Odogawa R, Tsuta K, et al Cancer related mutations in NRF2 impair its recognition by Keap1Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A 2008; 105:13568-73.
30. Kong AN, Owuor E, Yu R., Hebbar V, Chen C, Hu R., et al Induction of xenobiotic enzymes bythe MAP kinase pathway and the antioxidant or electrophile response element (ARE/EpRE). Drug Metab Rev 2001; 33: 255-71.
31. Lamb J. The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 2007; 7:54-60.
32. Lamb J, Crawford ED, Peck D, Modell J.W., Blat IC, Wrobel MJ, et al The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313:1929-35.
33. Hassane DC, Guzman ML, Corbett C, Li X., Abboud R, Young F, et al Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 2008; 111:5654-62.
34. Hassane DC, Sen S, Minhajuddin M., Rossi RM, Corbett CA, Balys M, et al Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood 2010; 116:5983-90.
35. Hieronymus H, Lamb J, Ross K.N., Peng XP, Clement C, Rodina A, et al Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006; 10:321-30.
36. Stegmaier K, Ross KN, Colavito S.A., O'Malley S, Stockwell BR, Golub TR Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat Genet 2004; 36:257-63.
37. Stegmaier K, Wong JS, Ross K.N., Chow KT, Peck D, Wright RD, et al Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med 2007; 4:e122.
38. Wei G, Twomey D, Lamb J., Schlis K, Agarwal J, Stam R.W., et al Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006; 10: 331-42.
39. Gupta AK, Bakanauskas VJ, Cerniglia G.J., Cheng Y., Bernhard EJ, Muschel RJ, et al The Ras radiation resistance pathway. Cancer Res 2001; 61:4278-82.
40. McKenna WG, Muschel RJ, Gupta A.K., Hahn SM, Bernhard EJ The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 2003; 22:5866-75.
41. Mitsuishi Y, Taguchi K, Kawatani Y., Shibata T, Nukiwa T, Aburatani H., et al Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 2012; 22:66-79.
42. Barbie DA, Tamayo P, Boehm J.S., Kim SY, Moody SE, Dunn IF, et al Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462:108-12.
43. Broad Institute. Molecular Signatures Database v4.0. Available from: http://www.broadinstitute.org/msigdb/.
44. Freed-Pastor W.A., Prives C. Mutant p53: one name, many proteins. Genes Dev 2012; 26:1268-86.
45. Brown JM, Wouters BG Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59:1391-9.
46. Pomp J, Wike JL, Ouwerkerk I.J., Hoogstraten C., Davelaar J, Schrier PI, et al Cell density dependent plating efficiency affects outcome and interpretation of colony forming assays. Radiother Oncol 1996; 40: 121-5.
47. Perez-Moreno P., Brambilla E, Thomas R., Soria JC Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012; 18:2443-51.
48. Hayakawa K, Mitsuhashi N, Hasegawa M., Saito Y, Sakurai H, Ohno T., et al The prognostic significance of immunohistochemically detected p53 protein expression in non-small cell lung cancer treated with radiation therapy. Anticancer Res 1998; 18:3685-8.
49. Langendijk H, Thunnissen E, Arends J.W., de Jong J, ten Velde G, Lamers R, et al Cell proliferation and apoptosis in stage III inoperable non-small cell lung carcinoma treated by radiotherapy. Radiother Oncol 2000; 56:197-207.
50. Matsuzoe D, Hideshima T, Kimura A., Inada K, Watanabe K, Akita Y., et al p53 mutations predict non-small cell lung carcinoma response to radiotherapy. Cancer Lett 1999; 135:189-94.